GRADE is a clinical trial comparing the effectiveness of 4 randomly-assigned glucose-lowering therapies (insulin glargine, glimepiride, liraglutide, sitagliptin) plus metformin in 5047 participants with type 2 diabetes over 4-7 yrs of follow-up on metabolic status, side effects, quality of life, ꞵ-cell function and vascular complications.

This study aims to conduct real-time syndromic disease surveillance and serosurveillance to estimate incidence and prevalence of COVID-19 among the general population and in subpopulations.

This is a cohort study to compare maternal morbidity and mortality among pregnant and postpartum women with COVID-19 with those without the infection, and also to compare morbidity and mortality of this cohort to pre-pandemic deliveries.

TODAY2 is the long term follow-up of the youth from TODAY, to track the progression of type 2 diabetes (T2D) and related comorbidities and complications in the TODAY cohort as they transition to young adulthood.

The network is designed to focus on clinical questions in maternal-fetal medicine and obstetrics, particularly with respect to the continuing problem of preterm birth.

The DPPOS aims to assess the long-term effects of interventions used in the Diabetes Prevention Program (DPP) on the development of type 2 diabetes and its complications.

The Antibacterial Resistance Leadership Group (ARLG) is an international cooperative clinical research network funded by NIAID to prioritize, design, and execute clinical research that will impact the prevention, diagnosis and treatment of infections caused by antibiotic-resistant bacteria.

The primary goal of the EDIC study is to assess the long-term benefits of early intensive blood glucose control on the future development of diabetes-related complications, in participants with type 1 diabetes originally enrolled in the Diabetes Control and Complications Trial (DCCT).

RISE includes 3 randomized clinical trials examining whether aggressive glucose lowering will lead to recovery of pancreas function (β-cell function) in adults and youth with impaired glucose tolerance (IGT) and early type 2 diabetes.

The main objective of this multi-center collaborative study is to evaluate sequencing (both whole exome sequencing [WES] and WGS) as a prenatal diagnostic tool in pregnancies with a structural anomaly and a negative or only non-causal karyotype/ chromosome microarray analysis (CMA). 

The Lifestyle Interventions for Expectant Moms (LIFE-Moms) Consortium is designed to determine, in pregnant women with overweight or obesity, whether various behavioral and lifestyle interventions reduce excessive gestational weight gain and subsequent adverse maternal and neonatal outcomes and obesity in offspring.
 

This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and elect Panorama microdeletion and aneuploidy screening as part of their routine care.
 

Since 2009, the DC Cohort is a longitudinal research project designed to collect clinical data from HIV-infected outpatients receiving care at fifteen clinics in the District of Columbia.

The Consortium supports exercise and/or medical nutrition intervention research designed to improve cancer treatment-related outcomes for therapies delivered with curative or life-extending intent to cancer survivors.

MeDOC is a trans-NCI research program with participation from 4 National Cancer Institute divisions, 5 research grants from different institutions, and a CoC. The goal is to advance the current understanding of cancer’s connection to obesity and metabolic dysregulation in order to improve screening and risk prediction.